Previous 10 | Next 10 |
Summary Having suffered through a sharp decline in earnings multiples, small cap growth stocks held up well in a volatile quarter marked by a sharp upward ratcheting of interest rates. The Strategy underperformed its benchmark, primarily due to weakness among health care holdings ...
Integra LifeSciences Holdings Corporation. (IART) Q3 2022 Earnings Conference Call October 26, 2022, 08:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Jan De Witte - President & Chief Executive Officer Carrie Anderson - Chief F...
The following slide deck was published by Integra LifeSciences Holdings Corporation in conjunction with their 2022 Q3 earnings call. For further details see: Integra LifeSciences Holdings Corporation 2022 Q3 - Results - Earnings Call Presentation
Integra LifeSciences Holdings press release ( NASDAQ: IART ): Q3 Non-GAAP EPS of $0.86 beats by $0.14 . Revenue of $385.19M (-0.4% Y/Y) beats by $6.87M . The Company completed the sale of its non-core traditional wound care business at the end of August 2022. ...
PRINCETON, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2022. Third Quarter 2022 Highlights Third...
Integra LifeSciences Holdings ( NASDAQ: IART ) is scheduled to announce Q3 earnings results on Wednesday, October 26th, before market open. The consensus EPS Estimate is $0.72 (-16.3% Y/Y) and the consensus Revenue Estimate is $378.32M (-2.2% Y/Y). Over the last 2 year...
PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2022 financial results on Wednesday, October 26, 2022, prior to the market open. In conjunction w...
PRINCETON, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today announced the appointment of Harvinder Singh as executive vice president and president of Integra’s international business. Mr. Singh brings a wealth of global heal...
PRINCETON, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today issued its inaugural Environmental, Social and Governance (ESG) report . The report includes 2021 performance highlights i...
Summary Investors have punished Integra LifeSciences in FY22, most recently following the recall of its CereLink monitors. The market priced in the downside swiftly and with deep effect, helping shares find a 52-week low. There's now a wide dislocation in measures of corporate...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
21.25%Change Percent:
Integra LifeSciences Holdings Corporation Company Name:
IART Stock Symbol:
NASDAQ Market:
Integra LifeSciences Holdings Corporation Website:
2024-07-29 18:00:04 ET Ryan Zimmerman from BTIG issued a price target of $22.00 for IART on 2024-07-29 16:12:00. The adjusted price target was set to $22.00. At the time of the announcement, IART was trading at $25.42. The overall price target consensus is at $51.17 with...
2024-07-29 17:15:01 ET BTIG analyst issues SELL recommendation for IART on July 29, 2024 04:12PM ET. IART was trading at $25.42 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 2 - Hold, 1 - Sell ...
2024-07-29 12:23:00 ET Shares of Integra Lifesciences (NASDAQ: IART) were sinking 15.5% as of 11 a.m. ET on Monday. The decline came after the medical technology company announced its second-quarter results before the market opened. Integra reported Q2 revenue of $418.2 million,...